Retour

Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome

- 22 janvier 2025 - 1  mn de lecture

The main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one’s type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one’s disorder.

En rapport Clinical Trials

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis – Study 1
22 janvier 2025 1  mn de lecture

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis – Study 1
Effects of triptorelin when given every 6-months under the skin to adult males with cancer in the prostate
22 janvier 2025 1  mn de lecture

Effects of triptorelin when given every 6-months under the skin to adult males with cancer in the prostate
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
22 janvier 2025 1  mn de lecture

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
22 janvier 2025 1  mn de lecture

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
A Study to Assess the Safety and Efficacy of IPN10200 of in Adult Participants With Upper Limb Spasticity.
22 janvier 2025 1  mn de lecture

A Study to Assess the Safety and Efficacy of IPN10200 of in Adult Participants With Upper Limb Spasticity.
Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.
22 janvier 2025 1  mn de lecture

Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
22 janvier 2025 1  mn de lecture

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
22 janvier 2025 1  mn de lecture

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic...
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
22 janvier 2025 1  mn de lecture

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
22 janvier 2025 1  mn de lecture

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer